Sign in
Active, not recruitingNo phase

Sporadic Inclusion Body Myositis Natural History Study

Key facts

Who runs it
University of California, Irvine
Where
Aurora, Baltimore, Boston, Columbus, Fairway, Houston, Los Angeles, Miami, Orange, Philadelphia, Portland, Seattle, and St Louis, United StatesSee the 13 sites
Trial code
Status
Active, not recruiting
People taking part
150 people enrolled
Started
11 Oct 2021
Expected to end
31 Mar 2027
Type of study
Observational
Record updated
27 May 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Ages 40 years and older
  • Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body myositis (sIBM)
  • Disease onset is within the past 10 years of the time of Baseline visit
  • Able to participate and comply with study related procedures
  • Able to provide written consent

Who cannot take part

  • Current or very recent use (within last 6 months of the Baseline visit) of immunomodulation or immunosuppression therapy
  • Current or very recent use (within last 90 days of the Baseline visit) of an investigational medication or therapy
  • Co-existing significant medical or surgical conditions that, in the opinion of the investigator, will influence study participation or alter natural history

Where in United States

  • University of ColoradoAurora, United States
  • Johns Hopkins UniversityBaltimore, United States
  • Brigham and Women's HospitalBoston, United States
  • Ohio State UniversityColumbus, United States
  • Kansas University Medical CenterFairway, United States
  • Nerve and Muscle Center of TexasHouston, United States
  • University of California, Los AngelesLos Angeles, United States
  • University of MiamiMiami, United States
  • University of California IrvineOrange, United States
  • University of PennsylvaniaPhiladelphia, United States
  • Oregon Health Science UniversityPortland, United States
  • University of WashingtonSeattle, United States
  • Washington University in St. LouisSt Louis, United States

About the trial

What the trial wants to find out

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Record updated
27 May 2026